FR2625677A1 - Medicinal composition intended for administration in aerosol form - Google Patents

Medicinal composition intended for administration in aerosol form Download PDF

Info

Publication number
FR2625677A1
FR2625677A1 FR8800234A FR8800234A FR2625677A1 FR 2625677 A1 FR2625677 A1 FR 2625677A1 FR 8800234 A FR8800234 A FR 8800234A FR 8800234 A FR8800234 A FR 8800234A FR 2625677 A1 FR2625677 A1 FR 2625677A1
Authority
FR
France
Prior art keywords
composition according
drug composition
weight
bronchodilator
total weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR8800234A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COSNIER ALAIN
Original Assignee
COSNIER ALAIN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by COSNIER ALAIN filed Critical COSNIER ALAIN
Priority to FR8800234A priority Critical patent/FR2625677A1/en
Publication of FR2625677A1 publication Critical patent/FR2625677A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Medicinal composition intended for administration in aerosol form, characterised in that it contains, by weight of the active principles: - from 50 to 99.995% of vegetable essential oils, - from 0.005 to 40% of bronchodilator substances, the sum of the constituents mentioned having to be equal to 100% by weight in each case. It is also characterised in that it contains ethyldiglycol in the proportion of 20 to 93% of the total weight of the composition and monopropylene glycol in the proportion of 1 to 40% of the total weight of the composition. Application envisaged: treatment and prevention of respiratory pathologies in animals or humans.

Description

COMPOSITION MEDICAMENTEUSE DESTINEE A ETRE ADMINISTREE SOUS
FORME D'AEROSOL
L'invention concerne une nouvelle composition médicamenteuse destinée à être administrée par voie aeridnne sous forme d'serosol. DRUG COMPOSITION TO BE ADMINISTERED UNDER
AEROSOL FORM
The invention relates to a new medicinal composition intended to be administered by aeridnne in the form of serosol.

L'invention concerne une composition médicamenteuse du type en question qui soit facile à préparer et à administrer et donne d'excellents résultats dans les traitements préventifs et curatifs spécialement comme antiseptique, antitussif, bronchodilatateur, mucolytique, fébrifuge, stimulant immunitaire, eupnéique, eutrophique, antiinflammatoire, tant pour l'animal que pour l'humain. The invention relates to a drug composition of the type in question which is easy to prepare and administer and gives excellent results in preventive and curative treatments especially as antiseptic, antitussive, bronchodilator, mucolytic, febrifuge, immune stimulant, eupneic, eutrophic, anti-inflammatory, for both animals and humans.

La recherche de compositions appropriées pour le traitement de divers types de maladies respiratoires a amené l'inventeur à étudier des compositions comprenant des substanoes antiseptiques, d'une part, et des substances bronchodilatatrices d'autre part, c'est à dire renfermant en combinaison des constituants du type de ceux rencontrés chez des huiles essentielles aromatiques ou des composés de synthèse et des substances sous forme d'extrait végétaux ou de synthèse. The search for suitable compositions for the treatment of various types of respiratory diseases led the inventor to study compositions comprising antiseptic substanoes, on the one hand, and bronchodilator substances on the other hand, ie containing in combination constituents of the type of those encountered in aromatic essential oils or synthetic compounds and substances in the form of plant or synthetic extract.

On rappelle que les huiles essentielles aromatiques sont des substances extraites de végétaux aromatiques répondant à certaines caractéristiques. Elles sont notamment de consistance huileuse, plus ou moins fluides, très odorantes, volatiles et plus légères que l'eau. It is recalled that aromatic essential oils are substances extracted from aromatic plants meeting certain characteristics. They are in particular of oily consistency, more or less fluid, very odorous, volatile and lighter than water.

La recherche effectuée par l'inventeur a également portée sur le procédé d'administration de telles spécialités . Il s'est avéré, de manière surprenante et inattendue, qu'en utilisant en combinaison certaines huiles essentielles ou d'autres substances antiseptiques, en les associant à certaines substances bronchodilatatrices et en les administrant par voie aérosol vrai, il était possible de disposer de compositions dans lesquelles les activités des constituants respectifs étaient potentialisées ce qui entraine avantageusement une efficacité thérapeutique sur un très large spectre.  The research carried out by the inventor also focused on the method of administration of such specialties. It turned out, surprisingly and unexpectedly, that by using in combination certain essential oils or other antiseptic substances, by associating them with certain bronchodilator substances and by administering them by true aerosol route, it was possible to have available compositions in which the activities of the respective constituents were potentiated, which advantageously results in therapeutic efficacy over a very broad spectrum.

Cette composition médicamenteuse à base de substances antiseptiques, et de substances bronchodilatatrices destinée à être administrée par voie aériene sous forme d'aerosol, se carctérise en ce qu'elle contient en poids des principes actifs:
- de 50 à 99.995 X d'une substance antiseptique
- de 0.005 à 50 X d'une substance à propriété bronchodilatatrice.This medicinal composition based on antiseptic substances, and bronchodilator substances intended to be administered by air in the form of an aerosol, is characterized in that it contains by weight of the active principles:
- from 50 to 99.995 X of an antiseptic substance
- from 0.005 to 50 X of a substance with bronchodilator property.

La somme des constituants indiqués devant, dans chaque cas, être égale à 100 X en poids.The sum of the components indicated must, in each case, be equal to 100 X by weight.

Parmi les substances antiseptiques utilisables on peut citer les huiles essentielles parmi lesquelles on peut citer l'huile de Pin (Pinus sylvester et Pinus pinaster) d'Eucalyptus (Eucalyptus globulus), de girofle (Eugenia caryophyllata), de térébenthine, de menthe, de sarriette de canelle de Ceylan, d'origan, d1 de géranium.  Among the antiseptic substances which can be used, there may be mentioned essential oils among which mention may be made of pine oil (Pinus sylvester and Pinus pinaster) of Eucalyptus (Eucalyptus globulus), cloves (Eugenia caryophyllata), turpentine, mint, Ceylon cinnamon savory, oregano, d1 geranium.

Avantageusement la composition en huiles essentielles est la suivante:
- au moins 30 % d'huile essentielle de térébenthine
- de 10 à 40 X d'huile essentielle d'eucalyptus
- de 3 à 30 X d'huile essentielle de Girofle
Les désignations ci-dessus comme les désignations des plantes données ci-après sont celles du Codex, c'est à dire du dictionnaire officiel en France dénommé aussi "Pharmacopée".Advantageously, the composition of essential oils is as follows:
- at least 30% turpentine essential oil
- from 10 to 40 X of eucalyptus essential oil
- from 3 to 30 X clove essential oil
The designations above as the designations of the plants given below are those of the Codex, ie of the official dictionary in France also called "Pharmacopée".

Comme on le sait, les huiles essentielles ont, pour certaines d'entre elles, des propriétés antiseptiques et antiinfectieuses. As we know, essential oils have, for some of them, antiseptic and antiinfectious properties.

Parmi les substances bronchodilatatrices utilisables on peut citer la lobéline, l'extrait fluide de lobélie, l'aleudrine, la néosynéphrine, la procaine, la benzedrine, la pervitine, le 2-aminoheptane, le 1-cyclopentyl-2 -methylaminopropane, l'éphédrine, la théophylline, la diprophylline, la bromhexine, l'atropine. Among the bronchodilator substances which can be used, there may be mentioned lobelin, the fluid extract of lobelia, aleudrine, neosynephrine, procaine, benzedrine, pervitin, 2-aminoheptane, 1-cyclopentyl-2 -methylaminopropane, ephedrine, theophylline, diprophylline, bromhexine, atropine.

Avantageusement cette composition-contient 85 X d'huiles essentielles végétales et 15 X d'extrait fluide de lobélie. Advantageously, this composition contains 85 X of vegetable essential oils and 15 X of lobelia fluid extract.

Pour rendre possible la diffusion de la composition sous forme d'aérosol, et pour la rendre homogène on ajoute à celle-ci un excipient à base de glycols et d'eau tel que la composition végétale représente entre 5 et 35 X du total.  To make possible the diffusion of the composition in aerosol form, and to make it homogeneous, an excipient based on glycols and water is added to it such that the vegetable composition represents between 5 and 35% of the total.

Parmi les glycols utilisables on peut citer
l'ethyldiglycol à raison de 20 à 93 % du poids total de la
composition, de préférence de 65 à 85 % et le monopropylène
glycol à raison de 1 à 40 X du poids total de la composi
tion de préférence de 3 à 10%.Among the glycols which can be used, mention may be made of
ethyldiglycol at 20 to 93% of the total weight of the
composition, preferably 65 to 85% and monopropylene
glycol at a rate of 1 to 40 X of the total weight of the compound
preferably 3 to 10%.

La proportion d'eau dans la composition finale sera
comprise entre 1 et 74X du poids total de préférence 8 à 12
%
Chacune des substances, est bien connue pour un certain nombre d'applications pharmaceutiques. La composition selon l'invention consiste à assembler ces constituants dans des proportions, sous des formes, et avec des excipients, déterminés et bien précis, de manière à provoquer une synergie et une interaction de ces composants entre eux. La composition finale de base obtenue, présente des effets et des résultats nettement améliorés par rapport ce que l'on obtenait avec chaque constituant pris isolément, ce qui est inattendu et surprenant.The proportion of water in the final composition will be
between 1 and 74X of the total weight preferably 8 to 12
%
Each of the substances is well known for a number of pharmaceutical applications. The composition according to the invention consists in assembling these constituents in proportions, in forms, and with excipients, determined and very precise, so as to bring about a synergy and an interaction of these components with one another. The final basic composition obtained has significantly improved effects and results compared to what was obtained with each constituent taken in isolation, which is unexpected and surprising.

On a constaté que l'on obtient d'excellents résultats avec une composition contenant:
- 2 grammes d'huile essentielle de girofle
- 3 grammes d'huile essentielle d'eucalyptus
- 6 grammes d'huile essentielle de terebenthine
- 2 grammes d'extrait fluide de lobélie
- 72 grammmes d'ethyl diglycol
- 5 grammes de monopropylène glycol
- 10 grammes d'eau adoucie
Dans une forme de réalisation perfectionnnée, cette composition contient également entre 2 et 10 % d'huile essentielle d'un ou de plusieurs des composés suivants: Cannelle de Ceylan, Citron, Lavande, Lavandin, Niaouli,Romarin, Thym, Origan, Coriandre, Cyprès, Géranium,
Menthe.It has been found that excellent results are obtained with a composition containing:
- 2 grams of clove essential oil
- 3 grams of eucalyptus essential oil
- 6 grams of turpentine essential oil
- 2 grams of fluid lobelia extract
- 72 grams of ethyl diglycol
- 5 grams of monopropylene glycol
- 10 grams of softened water
In an improved embodiment, this composition also contains between 2 and 10% of essential oil from one or more of the following compounds: Ceylon cinnamon, Lemon, Lavender, Lavandin, Niaouli, Rosemary, Thyme, Oregano, Coriander, Cypress, Geranium,
Mint.

Comme déjà dit, la composition médicamenteuse selon l'invention est administrée sous forme d'aerosol. A titre indicatif on obtient de bons résultats en faisant diffuser des quantités comprises entre 0.1 et 10 ml par m3 trois à 8 jours consécutifs. As already said, the drug composition according to the invention is administered in the form of an aerosol. As an indication, good results are obtained by distributing quantities of between 0.1 and 10 ml per m3 three to 8 consecutive days.

Les propriétés pharmacologiques des compositions médicamenteuses caractéristiques de l'invention sont essentiellement d'être antiseptiques, bactéricides, virucides, fongicides, bronchodilatatrices, mucolytiques, expectorantes, fébrifuges, immunostimulant, antitussif, eutrophique, stimulante de l'appétit, hépatoprotectrice, cholérétique
A titre d'application thérapeutique, pour l'animal ou l'humain, on peut citer le traitement et la prévention:
- de toutes les pathologies respiratoires quelle qu'en
soit l'étiologie
- du syndrôme de maladaptation en élevage dit industriel
La manière dont l'invention peut être réalisée ressortira mieux de l'exemple qui suit, donné à titre indicatif et non limitatif:
Dans une cuve inox de fabrication, on incorpore la totalité des principes actifs. On et l'agitation en marche,
On ajoute l'Ethyl Diglycol. On ajoute l'eau adoucie. On ajoute le Monopropylène glycol et on maintient sous agitation pendant une heure.The pharmacological properties of the characteristic drug compositions of the invention are essentially to be antiseptics, bactericides, virucides, fungicides, bronchodilators, mucolytics, expectorants, febrifuges, immunostimulant, cough suppressant, eutrophic, stimulant of appetite, hepatoprotective, choleretic
As a therapeutic application, for animals or humans, we can cite treatment and prevention:
- all respiratory pathologies whatever
either the etiology
- the maladaptation syndrome in so-called industrial farming
The manner in which the invention can be implemented will emerge more clearly from the following example, given by way of non-limiting example:
In a stainless steel manufacturing tank, all the active ingredients are incorporated. On and the restlessness in motion,
Ethyl Diglycol is added. Add the softened water. Monopropylene glycol is added and the mixture is stirred for one hour.

Lorsque le mélange est réalisé, on le met immédiatement en récipient hérmétique pour éviter une évaporation des substances aromatiques.  When the mixture is produced, it is immediately placed in a hermetic container to avoid evaporation of the aromatic substances.

Claims (10)

REVENDICATIONS 1/ Composition médicamenteuse destinée à être administrée sous forme d'aérosol, caractérisée en ce qu elle contient en poids des substances actives: 1 / Drug composition intended to be administered in the form of an aerosol, characterized in that it contains, by weight, active substances: - de 50 à 99,995 % d'une substance antiseptique - from 50 to 99.995% of an antiseptic substance - de 0,005 à 50 % de substances à propriétés bronchodilatatrices.  - from 0.005 to 50% of substances with bronchodilator properties. La somme des constituants indiqués devant dans chaque cas, être égale à 100 X en poidsThe sum of the components indicated must in each case be equal to 100 X by weight 2/ Composition médicamenteuse selon la revendication 1, caractérisée en ce qu'elle contient en poids des substances actives: 2 / medicinal composition according to claim 1, characterized in that it contains, by weight, active substances: - 85 X d'huiles essentielles végétales - 85 X of vegetable essential oils - 15 % d'extrait fluide de lobélie - 15% fluid lobelia extract 3/ Composition médicamenteuse selon les revendications et 2, caractérisée en ce qu'elle contient en poids des huiles essentielles:: 3 / Drug composition according to claims and 2, characterized in that it contains by weight essential oils: - Au moins 30 X d'huile essentielle de thérébentine - At least 30 X essential oil of therebentine - de 10 à 40 % d'huile essentielle d'eucalyptus - from 10 to 40% of eucalyptus essential oil (Eucalyptus globulus) (Eucalyptus globulus) - de 3 à 30 X d'huile essentielle de girofle (Eugenia - from 3 to 30 X essential oil of cloves (Eugenia cariophyllata) cariophyllata) 4/ Composition médicamenteuse selon l'une des revendications 1 à 3, caractérisée en ce qu'elle contient également de l'ethyl diglycol à raison de 20 à 93 % du poids total de la composition, de préférence 65 à 85 %. 4 / drug composition according to one of claims 1 to 3, characterized in that it also contains ethyl diglycol in an amount of 20 to 93% of the total weight of the composition, preferably 65 to 85%. 5/ Composition médicamenteuse selon l'une des revendications 1 à 4, caractérisée en ce qu'elle contient également du monopropylène glycol à raison de 1 à 40 % du poids total de la composition, de préférence 3 à 10 %  5 / drug composition according to one of claims 1 to 4, characterized in that it also contains monopropylene glycol in an amount of 1 to 40% of the total weight of the composition, preferably 3 to 10% 6/ Composition médicamenteuse selon l'une des revendications 1 à 5, caractérisée en ce qu'elle contient également de l'eau à raison de 1 à 74 X du poids total de la composition, de préférence 8 à 12 %.  6 / drug composition according to one of claims 1 to 5, characterized in that it also contains water in an amount of 1 to 74 X of the total weight of the composition, preferably 8 to 12%. 7/ Composition médicamenteuse selon l'une des revendications 1 à 6, caractérisée en ce qu'elle contient comme substance bronchodilatatrice de la lobéline à raison de 0.005 à 1 X du poids total de la composition, de préférence 0.01 à 0.1 X.  7 / drug composition according to one of claims 1 to 6, characterized in that it contains as a bronchodilator substance lobelin at a rate of 0.005 to 1 X of the total weight of the composition, preferably 0.01 to 0.1 X. 8/ Composition médicamenteuse selon l'une des 8 / Drug composition according to one of revendications 1 à 6, caractérisée en ce qu'elle contient Claims 1 to 6, characterized in that it contains comme substance bronchodilatatrice de l'aleudrine, as a bronchodilator of aleudrine, et/ou de la néosynéphrine et/ou de la procaine, et/ou and / or neosynephrine and / or procaine, and / or de la benzedrine, et/ou de la pervitine, et/ou du 2 benzedrine, and / or pervitin, and / or 2 -aminoheptane, et/ou du 1-cyclopentyl-2 -aminoheptane, and / or 1-cyclopentyl-2 -methylaminopropane,et/ou de l'éphédrine, et/ou de la -methylaminopropane, and / or ephedrine, and / or théophylline, et ou de la brbmhexine, et/ou de theophylline, and or brbmhexine, and / or l'atropine,et/ou de la diprophylline. atropine, and / or diprophylline. 9/ Composition médicamenteuse selon l'une des 9 / Drug composition according to one of revendications 1 à 8, caractérisée en ce qu'elle contient Claims 1 to 8, characterized in that it contains également des huiles essentielles de canelle et/ou also essential oils of cinnamon and / or d'origan et/ou de thym et/ou de géranium et/ou de menthe oregano and / or thyme and / or geranium and / or mint et/ou de sarriette à raison de 2 à 10%. and / or savory at 2 to 10%. 10/ Composition médicamenteuse selon l'une des 10 / Drug composition according to one of revendications 1 à 9, caractérisée en ce qu'elle exerce claims 1 to 9, characterized in that it exercises une activité thérapeutique dans toute pathologie therapeutic activity in any pathology respiratoire et d'adaptation comme antiseptique, respiratory and adaptation as an antiseptic, antitussif, immunostimulant, eupnéique, eutrophique, antitussive, immunostimulant, eupneic, eutrophic, antiinflammatoire, mucolytique, antitussif, anti-inflammatory, mucolytic, antitussive, bronchodilatateur.  bronchodilator.
FR8800234A 1988-01-07 1988-01-07 Medicinal composition intended for administration in aerosol form Withdrawn FR2625677A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR8800234A FR2625677A1 (en) 1988-01-07 1988-01-07 Medicinal composition intended for administration in aerosol form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8800234A FR2625677A1 (en) 1988-01-07 1988-01-07 Medicinal composition intended for administration in aerosol form

Publications (1)

Publication Number Publication Date
FR2625677A1 true FR2625677A1 (en) 1989-07-13

Family

ID=9362201

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8800234A Withdrawn FR2625677A1 (en) 1988-01-07 1988-01-07 Medicinal composition intended for administration in aerosol form

Country Status (1)

Country Link
FR (1) FR2625677A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414036B1 (en) 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
US7411005B2 (en) 2002-02-13 2008-08-12 Van Beek Natural Science, Llc Compositions and methods for increasing milk production in animals

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594296A (en) * 1948-06-24 1952-04-29 Aerosol Corp Lobeline aerosol dilating medicament
US2681880A (en) * 1951-10-25 1954-06-22 Aerosol Corp Aerosol dilating medical composition
US2868691A (en) * 1956-03-21 1959-01-13 Riker Laboratories Inc Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594296A (en) * 1948-06-24 1952-04-29 Aerosol Corp Lobeline aerosol dilating medicament
US2681880A (en) * 1951-10-25 1954-06-22 Aerosol Corp Aerosol dilating medical composition
US2868691A (en) * 1956-03-21 1959-01-13 Riker Laboratories Inc Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARZNEIMITTEL FORSCHUNG DRUG RESEARCH, vol. 37(II), no. 11, novembre 1987, pages 1258-1262, Verlag f}r Medizin und Naturwissenschaften GmbH, Aulendorf, DE; J.BERMUDEZ et al.: "Activity of the oxidation products of oleum terebinthinae "Landes" on Guinea Pig Airway smooth muscle in vivo and in vitro" *
LOUIS VIDAL: "DICTIONNAIRE VIDAL", 1961, page 140, Office de Vulgarisation Pharmaceutique, Paris, FR *
LOUIS VIDAL: "DICTIONNAIRE VIDAL", 1974, page 1686, Office de Vulgarisation Pharmaceutique, Paris, FR *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414036B1 (en) 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
US6649660B2 (en) 1999-09-01 2003-11-18 Van Beek Global/Ninkov L.L.C. Composition for treatment of infections of humans and animals
US7411005B2 (en) 2002-02-13 2008-08-12 Van Beek Natural Science, Llc Compositions and methods for increasing milk production in animals

Similar Documents

Publication Publication Date Title
CA1125172A (en) Pharmaceutical composition and process for its preparation
US7858570B2 (en) Compositions and methods for removing urushiol and treating the resulting skin condition
CA2395121C (en) Composition, in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method
CH625121A5 (en) Process for preparing an insecticidal shampoo
US11564963B2 (en) Topical compositions, process of large-scale manufacture, and method of use
FR2563109A1 (en) Phytotherapeutic composition composed of plants containing oils, plants containing mineral salts, plants containing waxes, oxidases and mineral salts, which treats diseases of the airways, and process for preparing it
Ansari et al. Therapeutics and pharmacology of Gul-e-Surkh (Rosa damascena Mill): An important Unani drug
Belkhodja et al. In vitro and in vivo anti-inflammatory potential of eucalyptus globulus essential oil
ES2281569T3 (en) EYE DROPS.
CA2283122A1 (en) Plant extract compositions, method of preparation, and pharmaceutical compositions containing them
AP707A (en) Aromatic composition based on olibanum combined with a synergic agent (e.g. Eucalyptol, borneol, zinc salt, copper salt) and use thereof.
US5665360A (en) Method of treating peripheral neuropathies of the feet and legs
FR2830198A1 (en) Compositions containing Ravensara aromatica essential oil and one or more other essential oils for treatment of viral, fungal, and parasitic infections, cystic fibrosis, AIDS, and certain tumors
FR2625677A1 (en) Medicinal composition intended for administration in aerosol form
FR2748204A1 (en) Antiseptic use of distilled Melaleuca essential oil
RU2147223C1 (en) Agent for treatment of parodontium disease and method of its preparing
FR2759546A1 (en) Use of citronella components as insecticides
JPH10298097A (en) Schistosomiasis haematobia-treating agent
US20040146587A1 (en) Topical composition for relief of pain and minor skin irritations
FR2623397A1 (en) Plant-based medicinal composition for internal use
Akbar et al. Santalum album L.(Santalaceae)
Olsen Australian tea tree oil guide: First aid kit in a bottle
EP1967177A2 (en) Dermocosmetic composition for pets
EP0083285A1 (en) Analgesic composition comprising at least one acid alcohol phthalate neutralized by a base
RU2299726C2 (en) Curative-prophylactic anti-infectious labial pomade

Legal Events

Date Code Title Description
ST Notification of lapse